Journal article

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases

Michael C Heinrich, Heikki Joensuu, George D Demetri, Christopher L Corless, Jane Apperley, Jonathan A Fletcher, Denis Soulieres, Stephan Dirnhofer, Amy Harlow, Ajia Town, Arin McKinley, Shane G Supple, John Seymour, Lilla Di Scala, Allan van Costerom, Richard Herrmann, Zariana Nikolova, Grant McArthur

CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2008

Abstract

PURPOSE: To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases. EXPERIMENTAL DESIGN: This was a phase II, open-label, single arm study. Patients > or = 15 years old with malignancies showing histologic or molecular evidence of expression/activation of imatinib-sensitive tyrosine kinases were enrolled. Patients were treated with 400 or 800 mg/d imatinib for hematologic malignancy and solid tumors, respectively. Treatment was continued until disease progression or unacceptable toxicity. The primary objective was to identify evidence of imatinib activity with tumor response as the primary end point. RE..

View full abstract